These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 27136061)

  • 1. Recent progress in the development of Toll-like receptor (TLR) antagonists.
    Patra MC; Choi S
    Expert Opin Ther Pat; 2016 Jun; 26(6):719-30. PubMed ID: 27136061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor modulators: a patent review (2006-2010).
    Basith S; Manavalan B; Lee G; Kim SG; Choi S
    Expert Opin Ther Pat; 2011 Jun; 21(6):927-44. PubMed ID: 21406035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor agonists: a patent review (2011 - 2013).
    Hussein WM; Liu TY; Skwarczynski M; Toth I
    Expert Opin Ther Pat; 2014 Apr; 24(4):453-70. PubMed ID: 24456079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics.
    Gomariz RP; Gutiérrez-Cañas I; Arranz A; Carrión M; Juarranz Y; Leceta J; Martínez C
    Curr Pharm Des; 2010; 16(9):1063-80. PubMed ID: 20030612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic and therapeutic implications of toll-like receptor ligands.
    Hedayat M; Takeda K; Rezaei N
    Med Res Rev; 2012 Mar; 32(2):294-325. PubMed ID: 22383179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptors: promising therapeutic targets for inflammatory diseases.
    Achek A; Yesudhas D; Choi S
    Arch Pharm Res; 2016 Aug; 39(8):1032-49. PubMed ID: 27515048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists.
    Keshavarz A; Pourbagheri-Sigaroodi A; Zafari P; Bagheri N; Ghaffari SH; Bashash D
    IUBMB Life; 2021 Jan; 73(1):10-25. PubMed ID: 33217774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition of nucleic acids by Toll-like receptors and development of immunomodulatory drugs.
    Kuznik A; Panter G; Jerala R
    Curr Med Chem; 2010; 17(18):1899-914. PubMed ID: 20377514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells.
    Tartey S; Takeuchi O
    Int Rev Immunol; 2017 Mar; 36(2):57-73. PubMed ID: 28060562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting negative regulation of Toll-like receptor signaling.
    Kondo T; Kawai T; Akira S
    Trends Immunol; 2012 Sep; 33(9):449-58. PubMed ID: 22721918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Toll-like receptors with small molecule agents.
    Wang X; Smith C; Yin H
    Chem Soc Rev; 2013 Jun; 42(12):4859-66. PubMed ID: 23503527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of toll-like receptors in gastrointestinal inflammation.
    Ishihara S; Rumi MA; Ortega-Cava CF; Kazumori H; Kadowaki Y; Ishimura N; Kinoshita Y
    Curr Pharm Des; 2006; 12(32):4215-28. PubMed ID: 17100624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.
    Li TT; Ogino S; Qian ZR
    World J Gastroenterol; 2014 Dec; 20(47):17699-708. PubMed ID: 25548469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of Toll-like receptors in multiple sclerosis and possible targeting for therapeutic purposes.
    Gooshe M; Abdolghaffari AH; Gambuzza ME; Rezaei N
    Rev Neurosci; 2014; 25(5):713-39. PubMed ID: 24914714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAGE and TLRs: relatives, friends or neighbours?
    Ibrahim ZA; Armour CL; Phipps S; Sukkar MB
    Mol Immunol; 2013 Dec; 56(4):739-44. PubMed ID: 23954397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basic understanding and therapeutic approaches to target toll-like receptors in cancerous microenvironment and metastasis.
    Khajeh Alizadeh Attar M; Anwar MA; Eskian M; Keshavarz-Fathi M; Choi S; Rezaei N
    Med Res Rev; 2018 Sep; 38(5):1469-1484. PubMed ID: 29283184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-Molecule Modulators of Toll-like Receptors.
    Wang Y; Zhang S; Li H; Wang H; Zhang T; Hutchinson MR; Yin H; Wang X
    Acc Chem Res; 2020 May; 53(5):1046-1055. PubMed ID: 32233400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity.
    Krieg AM; Vollmer J
    Immunol Rev; 2007 Dec; 220():251-69. PubMed ID: 17979852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-Like Receptor Pathways in Autoimmune Diseases.
    Chen JQ; Szodoray P; Zeher M
    Clin Rev Allergy Immunol; 2016 Feb; 50(1):1-17. PubMed ID: 25687121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.